CA - Medexus Pharmaceuticals announces C$10M offering
2023-09-06 06:34:13 ET
Medexus Pharmaceuticals ( OTCQX:MEDXF ) entered into an agreement with Research Capital as sole bookrunner and sole underwriter, pursuant to which the underwriter has agreed to purchase, on a bought-deal basis, 3.34M units at a price of C$2.95 per unit.
Gross proceeds of ~C$10M.The net proceeds will be used for working capital and general corporate purposes.
Underwriters have the option to purchase up to 15% more units.The closing is expected to occur on or about September 21, 2023.
More on Medexus Pharmaceuticals
- Seeking Alpha’s Quant Rating on Medexus Pharmaceuticals
- Financial information for Medexus Pharmaceuticals
For further details see:
Medexus Pharmaceuticals announces C$10M offering